Go online to PeerView.com/SFE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert pathologist discusses secondary acute myeloid leukemia (AML) as well as the modern tools used in diagnostic assessment that can help facilitate appropriate risk stratification and collaborative treatment decisions so therapies beyond conventional chemotherapy options can be considered. Upon completion of this accredited CE activity, participants should be better able to: Summarize clinical, molecular/genetic, and pathologic features of secondary AML/AML-MRC that can be used to confirm a diagnosis and distinguish this disorder from other subtypes, Describe the testing tools and methods that can be used to capture the morphologic and molecular features of secondary AML/AML-MRC, Cite efficacy and safety evidence surrounding the use of novel therapeutics in patients with secondary AML, Develop a diagnostic and risk-stratification strategy in consultation with treating clinicians once a diagnosis of AML is suspected so a definitive diagnosis of secondary AML can be rendered and appropriate therapies can be selected.